Join our daily newsletter At The Bell to receive exclusive market insights
- Imagion Biosystems (IBX) will close its MagSense HER2 imaging agent phase one clinical study after achieving its enrolment target of 13 patients
- IBX uses nanoparticle technology to alter how magnetic resonance imaging (MRI) and its proprietary magnetic relaxometry technology can detect specific tumours
- Data from Imagion’s MagSense HER2 revealed no signs of toxicity nor adverse reactions
- The company plans to lodge an investigational new drug (IND) application for its MagSense HER2 early next year
- IBX shares are up 41.7 per cent, trading at 1.7 cents at 10:45 am AEST
Imagion Biosystems (IBX) has initiated plans to close its MagSense HER2 imaging agent clinical study after achieving its enrolment target.
IBX enrolled 13 patients in its phase one clinical study, which used the company’s nanoparticle technology to alter how magnetic resonance imaging (MRI) can detect specific cancers.
Data from Imagion’s MagSense HER2 revealed no signs of toxicity, and no adverse reactions among the company’s proprietary magnetic relaxometry technology and conventional MRI employed in the study.
The company noted the change in image contrast in nodes highly suspicious of being cancerous is distinctly different from contrasts seen in non-cancerous nodes.
IBX said the study was “instrumental” in revealing the potential clinical use of the MagSense HER2 imaging agent, and the company intends to close enrolments fully by July 31, 2023.
“Completing the target enrolment numbers for the phase one study is a great achievement for our first clinical study,” Imagion CEO Bob Proulx said.
“Whilst recruitment has been challenging, by all accounts the phase one study has been a success, and we truly thank the breast cancer patients that volunteered to participate and the study investigators and staff that have diligently worked with us,” Mr Proulx said.
“We have truly broken new ground, having done something in medical imaging never done before.”
Mr Proulx said the results from phase one provided a “strong focus” for IBX to move forward with a phase two HER2 breast cancer program in the US.
The company also plans to publish the results in due course before using the data to lodge an investigational new drug (IND) application by early 2024.
IBX shares were up 41.7 per cent, trading at 1.7 cents at 10:45 am AEST.
